Boston Life Science Venture was founded in 2003, with a capital of NT$2 billions. The investment scopes of IBTB aim at pharmaceuticals, biopharmaceuticals, medical devices, agriculture biotechnology, and healthcare services. The cash-out enterprises in the portfolio have created 9~24% IRR and 1.2~1.4 Multiples. With the growing aging populations in developed countries, the medical expenditures expect to be rising rapidly and stimulate the development of bio-tech industries.